Lepu Medical's NeoVas Bioresorbable Scaffold Shown to Be Noninferior to Metallic Drug-Eluting Stents


February 12, 2018—Findings from a randomized controlled trial show that the NeoVas bioresorbable scaffold (BRS; Lepu Medical Technology (Beijing) Co., Ltd.) is noninferior to a cobalt-chromium everolimus-eluting stents (CoCr-EES) at the primary endpoint of 1-year angiographic in-segment late loss (LL). The data were published by Yaling Han et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2018;11:260–272).

According to researchers, the study objective was to evaluate the safety and efficacy of the NeoVas BRS because BRSs have the potential to improve very late outcomes compared with metallic drug-eluting stents. However, some BRSs have been associated with increased rates of device thrombosis before complete bioresorption. NeoVas is a new poly-L-lactic acid BRS that elutes sirolimus from a poly-D, L-lactide coating.

The study design included 560 patients with a single de novo native coronary artery lesion with a reference vessel diameter between 2.5 to 3.75 mm and a lesion length ≤ 20 mm randomized 1:1 at 32 centers to treatment with NeoVas (n = 278) versus CoCr-EES (n = 282). The primary endpoint was angiographic in-segment LL at 1 year; the major secondary endpoint was the rate of angina. Baseline and 1-year follow-up optical coherence tomography and fractional flow reserve were performed in a prespecified subgroup of patients.

In JACC: Cardiovascular Interventions, investigators reported 1-year in-segment LL was 0.14 ± 0.36 mm versus 0.11 ± 0.34 mm (difference, 0.03 mm; upper 1-sided 97.5% confidence interval, 0.09 mm; P noninferiority < .0001; P superiority = .36) in NeoVas and CoCr-EES, respectively. In both groups, clinical outcomes at 1 year and the rates of recurrent angina were similar (27.9% vs. 32.1%; P = .26). Optical coherence tomography at 1 year demonstrated a higher proportion of covered struts (98.7% vs 96.2%; P < .001), less strut malapposition (0% vs 0.6%; P < .001), and a smaller minimal lumen area (4.71 ± 1.64 mm2 vs 6 ± 2.15 mm2; P < .001) in NeoVas compared with CoCr-EES, respectively. Nonsignificant differences in fractional flow reserve (0.89 ± 0.08 vs 0.91 ± 0.06; P = .07) were also reported.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.